Steven Powell

Plethora Solutions Holdings Plc operates as a pharmaceutical company. It engages in the development and marketing of products for the treatment and management of urological disorders. The firm operates through the Plethora Development and The Urology Co. segments. The Plethora Development segment develops new pharmaceutical products. The Urology Co. segment sells and markets pharmaceutical and healthcare products. The company was founded by Michael Grant Wyllie and Neil Brent Stafford in December 2003 and is headquartered in Chalgrove, the United Kingdom.

Gilde Investment Management BV is an Independent Private Equity firm founded in 1982. Gilde Investment Management BV is headquartered in Utrecht.

Radiometer A/S develops as well as manufactures blood gas instruments and support devices. It supplies blood gas analyzers that measure blood gases and other parameters used to diagnose critically ill patients. It also provides accessories, IT systems and support services for blood gas testing, besides producing instruments that measure blood gases transcutaneously. The company consists of three subsidiaries Radiometer Medical ApS (Denmark), SenDx Medical, Inc. (US) and Radiometer Basel AG (Switzerland). Radiometer was founded in 1935 and is headquartered in Br?nsh?j, Denmark.

Whatman Ltd. develops, manufactures, and markets separation technology used for filtration, purification and storage of chemicals, and other liquids, and samples. The company was founded in 1740 by James Whatman and Ann Harris and is headquartered in Kent, UK.

Cambridge Cognition Ltd. operates as a neuroscience technology company delivering near-patient assessment solutions to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders. It offers CANTAB Tests and Services, CANTAB mobile and CANTABeclipse. The company was founded in 2002 and is headquartered in Cambridge, GB.

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.